Investigating how a specific protein interaction affects cancer progression
Chemical Biology of the Control of Neddylation by DCN1
['FUNDING_R01'] · UNIVERSITY OF KENTUCKY · NIH-10655433
This study is looking at how a protein called DCN1 helps control other proteins that are important for keeping cells healthy, especially in certain types of cancer, and it aims to find new ways to treat these cancers.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-10655433 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the DCN1 protein in regulating a group of proteins known as cullin RING ubiquitin ligases (CRLs), which are crucial for controlling the stability and function of various proteins in cells. By developing chemical and biological probes, the researchers aim to explore how the interaction between DCN1 and UBE2M influences cancer development, particularly in squamous cell carcinomas. The study will utilize both cellular models and mouse genetics to validate findings and potentially identify new therapeutic targets for cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with squamous cell carcinoma or other cancers where the DCN1 protein plays a significant role.
Not a fit: Patients with cancers unrelated to the mechanisms being studied, or those without a diagnosis of malignancy, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antitumor drugs targeting the DCN1-UBE2M interaction, offering hope for improved cancer treatments.
How similar studies have performed: Previous research has shown promise in targeting similar protein interactions in cancer, indicating that this approach could yield significant advancements.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GUY, RODNEY KIPLIN — UNIVERSITY OF KENTUCKY
- Study coordinator: GUY, RODNEY KIPLIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.